@article{39e30dbbdec94ec5bd7e6ca7f47ba7e4,
title = "Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool",
abstract = "Background: Previously, consensus MS care standards were defined by MS specialist neurologists from 19 countries. We developed, piloted and refined an Excel-based quality improvement tool to enable MS services to benchmark against these standards. Here, we examine the refined tool. Objective: To determine the applicability of the quality improvement tool in different healthcare settings. Methods: MS centres across the globe were invited to pilot the quality improvement tool by coding the medical records of 36 adults with MS. We invited feedback on user friendliness, quality improvement tool usefulness and relevance of data collected. Results: Seventeen centres from 14 countries participated; 14 completed the post-service evaluation survey. Over 50\% of responders rated the tool {\textquoteleft}very easy{\textquoteright} or {\textquoteleft}easy{\textquoteright} to use and {\textquoteleft}very relevant{\textquoteright} to their service. Almost 85\% of responders (11/13) planned to introduce changes to their service, including improvements in documentation, communication, interactions with colleagues and referrals; 85\% would use a future shorter version of the tool. Conclusions: The quality improvement tool can enable MS centres globally to benchmark their services. Widespread uptake of a shorter tool may help MS centres to work towards achieving consensus standards for brain health-focused care. Incorporation into routine clinical practice would drive adoption.",
keywords = "Benchmarking, consensus standards, data collection, medical records, patient care, quality improvement",
author = "Jeremy Hobart and Helmut Butzkueven and Jodi Haartsen and Tjalf Ziemssen and Thirusha Lane and Gavin Giovannoni",
note = "Funding Information: T Ziemssen has received grants from Biogen, Novartis, Sanofi and Teva, and personal fees from Almirall, Alexion, Celgene, Novartis, Sanofi, Teva, Merck, Roche and Viatris. Funding Information: The authors would like to thank the MS centres that participated in this pilot study. Dr Heather Lang of Oxford PharmaGenesis, Oxford, UK, developed the Excel-based workbook; Dr Emily Stock of PharmaGenesis London, UK, and Ruth Bentley, Independent Consultant, UK, provided medical writing and editorial support. All three were funded by Oxford Health Policy Forum, on behalf of the MS Brain Health initiative. The authors disclosed reimbursement to Oxford PharmaGenesis, which provided research, writing and editing support in the development of this article: This research was commissioned by Oxford Health Policy Forum, on behalf of the MS Brain Health initiative. Grants to support MS Brain Health were provided by Actelion Pharmaceuticals, Biogen, Bristol Myers Squibb, F. Hoffmann-La Roche and Merck KGaA, all of whom had no role in study design, data collection, data analysis, data interpretation, writing of the report or in the decision to submit the paper for publication. All authors had full access to the data in the study and the corresponding author had the final responsibility for the decision to submit for publication. Funding Information: H Butzkueven's institution receives compensation for advisory board, steering committee and educational activities from Biogen, Merck, Novartis and Roche. His institution receives research support from Biogen, Novartis, Medical Research Future Fund and National Health and Medical Research Council Australia, MS Research Australia and Roche. He receives personal compensation from Oxford Health Policy Forum for serving in the steering group of MS Brain Health. Funding Information: G Giovannoni has received consulting fees from AbbVie, Atara Bio, Bayer HealthCare, Biogen, Canbex Therapeutics, Five Prime Therapeutics, GlaxoSmithKline, GW Pharma, Japanese Tobacco, Merck, Merck Serono, Novartis, Oxford PharmaGenesis, Protein Discovery Laboratories, Roche, Sanofi Genzyme, Synthon, Teva Neuroscience and UCB, and grant/research support from Bayer HealthCare, Biogen, Merck, Merck Serono, Novartis and Sanofi Genzyme. Publisher Copyright: {\textcopyright} The Author(s), 2022.",
year = "2022",
month = jul,
doi = "10.1177/20552173221124023",
language = "English",
volume = "8",
journal = "Multiple Sclerosis Journal - Experimental, Translational and Clinical",
issn = "2055-2173",
publisher = "SAGE Publications Ltd",
number = "3",
}